PARP1 and colorectal carcinoma: In summary, our study identified novel PARPi lead structures with potent PARP-1 inhibitory activity in CRC cells but low cytotoxicity in wildtype CRC cells and no adverse effects on normal HCEC due to lack of PARP trapping.